Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 55 articles:
HTML format
Text format



Single Articles


    August 2017
  1. RAGHAVAN S, Mehta P, Ward MW, Bregenzer ME, et al
    Personalized Medicine Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Clin Cancer Res. 2017 Aug 16. pii: clincanres.0133.2017.
    PubMed     Text format     Abstract available


  2. LIU J, Agopiantz M, Poupon J, Wu Z, et al
    Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0861.2017.
    PubMed     Text format     Abstract available


  3. CORNELISON R, Dobbin ZC, Katre AA, Jeong DH, et al
    TARGETING RNA-POLYMERASE I IN BOTH CHEMOSENSITIVE AND CHEMORESISTANT POPULATIONS IN EPITHELIAL OVARIAN CANCER.
    Clin Cancer Res. 2017 Aug 4. pii: clincanres.0282.2017.
    PubMed     Text format     Abstract available


  4. WEIGELT B, Comino-Mendez I, de Bruijn I, Tian L, et al
    Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    Clin Cancer Res. 2017 Aug 1. pii: clincanres.0544.2017.
    PubMed     Text format     Abstract available


    July 2017
  5. BALASUBRAMANIAM S, Beaver JA, Horton S, Fernandes LL, et al
    FDA Approval Summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1337.2017.
    PubMed     Text format     Abstract available


    June 2017
  6. YANG WL, Gentry-Maharaj A, Simmons AR, Ryan A, et al
    Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Clin Cancer Res. 2017 Jun 21. pii: clincanres.0284.2017.
    PubMed     Text format     Abstract available


  7. HU Q, Hisamatsu T, Hammerle M, Cho MS, et al
    Role of platelet-derived Tgfbeta1 in the progression of ovarian cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3272.2016.
    PubMed     Text format     Abstract available


    March 2017
  8. WANG C, Armasu SM, Kalli KR, Maurer MJ, et al
    Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.0246.2017.
    PubMed     Text format     Abstract available


    February 2017
  9. LHEUREUX S, Lai Z, Dougherty BA, Runswick S, et al
    Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization.
    Clin Cancer Res. 2017 Feb 21. pii: clincanres.2615.2016.
    PubMed     Text format     Abstract available


  10. NG C, Zhang Z, Lee SI, Marques HS, et al
    CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.1859.2016.
    PubMed     Text format     Abstract available


  11. KOMMOSS S, Winterhoff B, Oberg A, Konecny GE, et al
    Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.
    Clin Cancer Res. 2017 Feb 3. pii: clincanres.2196.2016.
    PubMed     Text format     Abstract available


    January 2017
  12. SKATES SJ, Greene MH, Buys SS, Mai PL, et al
    Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2750.2015.
    PubMed     Text format     Abstract available


  13. ANDERSEN CL, Sikora MJ, Boisen MM, Ma T, et al
    Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.1501.2016.
    PubMed     Text format     Abstract available


    December 2016
  14. KIM H, George E, Ragland RL, Rafail S, et al
    Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
    Clin Cancer Res. 2016 Dec 19. pii: clincanres.2273.2016.
    PubMed     Text format     Abstract available


  15. CHATTERJEE J, Dai W, Abd Aziz NH, Teo PY, et al
    Clinical use of programmed cell death-1 (PD-1) and its ligand (PD-L1) expression as discriminatory and predictive markers in ovarian cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2366.2016.
    PubMed     Text format     Abstract available


    November 2016
  16. VANDERSTICHELE A, Busschaert P, Smeets D, Landolfo C, et al
    Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses.
    Clin Cancer Res. 2016 Nov 14. pii: clincanres.1078.2016.
    PubMed     Text format     Abstract available


  17. MARTINI P, Paracchini L, Caratti G, Mello-Grand M, et al
    lncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: a retrospective and multicentric study.
    Clin Cancer Res. 2016 Nov 8. pii: clincanres.1402.2016.
    PubMed     Text format     Abstract available


    October 2016
  18. BACHMAYR-HEYDA A, Aust S, Auer K, Meier SM, et al
    Integrative Systemic and Local Metabolomics with Impact on Survival in High Grade Serous Ovarian Cancer.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1647.2016.
    PubMed     Text format     Abstract available


  19. MONK BJ, Facciabene A, Brady WE, Aghajanian C, et al
    Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.1453.2016.
    PubMed     Text format     Abstract available


  20. MCCORMICK A, Donoghue P, Dixon M, O'Sullivan R, et al
    Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.0564.2016.
    PubMed     Text format     Abstract available


    September 2016
  21. ZHOU J, Alfraidi A, Zhang S, Santiago-O'Farrill J, et al
    A novel compound ARN-3236 inhibits Salt Inducible Kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1562.2016.
    PubMed     Text format     Abstract available


  22. FLANAGAN JM, Wilson A, Koo C, Masrour N, et al
    Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in ovarian cancer patients.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.1754.2016.
    PubMed     Text format     Abstract available


  23. AU-YEUNG G, Lang F, Azar WJ, Mitchell C, et al
    Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition.
    Clin Cancer Res. 2016 Sep 23. pii: clincanres.0620.2016.
    PubMed     Text format     Abstract available


  24. MARTIGNETTI JA, Chen Y, Camacho C, Silvers TR, et al
    INHIBITION OF THE NUCLEAR EXPORT RECEPTOR XPO1 AS A THERAPEUTIC TARGET FOR PLATINUM RESISTANT OVARIAN CANCER.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1333.2016.
    PubMed     Text format     Abstract available


  25. LO CS, Sanii S, Kroeger DR, Milne K, et al
    Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1433.2016.
    PubMed     Text format     Abstract available


    August 2016
  26. LIU JF, Palakurthi S, Zeng Q, Zhou S, et al
    Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for pre-clinical evaluation of novel therapeutics.
    Clin Cancer Res. 2016 Aug 29. pii: clincanres.1237.2016.
    PubMed     Text format     Abstract available



  27. Correction: Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver.
    Clin Cancer Res. 2016;22:4272.
    PubMed     Text format    


  28. BANDERA EV, Lee VS, Rodriguez-Rodriguez L, Powell B, et al
    RACIAL/ETHNIC DISPARITIES IN OVARIAN CANCER TREATMENT AND SURVIVAL.
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1119.2016.
    PubMed     Text format     Abstract available


    July 2016
  29. PERALES-PUCHALT A, Svoronos N, Rutkowski MR, Allegrezza MJ, et al
    FOLLICLE-STIMULATING HORMONE RECEPTOR IS EXPRESSED BY MOST OVARIAN CANCER SUBTYPES AND IS A SAFE AND EFFECTIVE IMMUNOTHERAPEUTIC TARGET.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0492.2016.
    PubMed     Text format     Abstract available


  30. SKATES SJ
    EPIC Early Detection of Ovarian Cancer.
    Clin Cancer Res. 2016 Jul 14. pii: clincanres.1391.2016.
    PubMed     Text format     Abstract available


  31. HORIKAWA N, Abiko K, Matsumura N, Hamanishi J, et al
    Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.0387.2016.
    PubMed     Text format     Abstract available


    June 2016
  32. IKEDA Y, Park JH, Miyamoto T, Takamatsu N, et al
    T-LAK cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in ovarian cancer.
    Clin Cancer Res. 2016 Jun 22. pii: clincanres.0207.2016.
    PubMed     Text format     Abstract available


  33. HOOGSTINS CE, Tummers QR, Gaarenstroom KN, de Kroon CD, et al
    A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer.
    Clin Cancer Res. 2016;22:2929-38.
    PubMed     Text format     Abstract available


    April 2016
  34. TIPER IV, Temkin SM, Spiegel S, Goldblum SE, et al
    VEGF potentiates GD3-mediated immune suppression by human ovarian cancer cells.
    Clin Cancer Res. 2016 Apr 13. pii: clincanres.2518.2015.
    PubMed     Text format     Abstract available


  35. TERRY KL, Schock H, Fortner RT, Husing A, et al
    A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort.
    Clin Cancer Res. 2016 Apr 8. pii: clincanres.0316.2016.
    PubMed     Text format     Abstract available


    January 2016
  36. BONITO NA, Borely J, Wilhelm-Benartzi C, Ghaem-Maghami S, et al
    Epigenetic regulation of the homeobox gene MSX1 associates with platinum resistant disease in high grade serous epithelial ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.1669.2015.
    PubMed     Text format     Abstract available


  37. KROEGER DR, Milne K, Nelson BH
    Tumor infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T cell responses, and superior prognosis in ovarian cancer.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2762.2015.
    PubMed     Text format     Abstract available


    November 2015
  38. LAMBERTS TE, Menke-van der Houven van Oordt CW, Ter Weele EJ, Bensch F, et al
    ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
    Clin Cancer Res. 2015 Nov 20. pii: clincanres.1272.2015.
    PubMed     Text format     Abstract available


  39. SINHA D, Chong L, George J, Schlueter H, et al
    Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients.
    Clin Cancer Res. 2015 Nov 20. pii: clincanres.1931.2015.
    PubMed     Text format     Abstract available


  40. KANG Y, Nagaraja AS, Armaiz-Pena GN, Dorniak PL, et al
    Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer.
    Clin Cancer Res. 2015 Nov 18. pii: clincanres.1275.2015.
    PubMed     Text format     Abstract available


    October 2015
  41. HEW K, Miller PC, El-Ashry D, Sun J, et al
    MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer.
    Clin Cancer Res. 2015 Oct 19. pii: clincanres.0534.2015.
    PubMed     Text format     Abstract available


    September 2015
  42. WOUTERS MC, Komdeur FL, Workel HH, Klip HG, et al
    Treatment regimen, surgical outcome and T cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high grade serous ovarian cancer.
    Clin Cancer Res. 2015 Sep 18. pii: clincanres.1617.2015.
    PubMed     Text format     Abstract available


    August 2015
  43. ZHONG Q, Peng HL, Zhao X, Zhang L, et al
    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.
    Clin Cancer Res. 2015;21:3807.
    PubMed     Text format    


  44. GONG L, Dong C, Ouyang W
    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.
    Clin Cancer Res. 2015;21:3806.
    PubMed     Text format    


    July 2015
  45. YANG JY, Werner HM, Li J, Westin SN, et al
    Integrative Protein-Based Prognostic Model for Early Stage Endometrioid Endometrial Cancer.
    Clin Cancer Res. 2015 Jul 29. pii: clincanres.0104.2015.
    PubMed     Text format     Abstract available


  46. KIM G, Ison G, McKee AE, Zhang H, et al
    FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
    Clin Cancer Res. 2015 Jul 17. pii: clincanres.0887.2015.
    PubMed     Text format     Abstract available


  47. TEWARI KS, Eskander RN, Monk BJ
    Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
    Clin Cancer Res. 2015 Jul 13. pii: clincanres.0088.2015.
    PubMed     Text format     Abstract available


  48. LIN K, Rubinfeld B, Zhang C, Firestein R, et al
    Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
    Clin Cancer Res. 2015 Jul 8. pii: clincanres.3383.2014.
    PubMed     Text format     Abstract available


  49. JOHNATTY S, Tyrer JP, Kar SP, Beesley J, et al
    Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium.
    Clin Cancer Res. 2015 Jul 7. pii: clincanres.0632.2015.
    PubMed     Text format     Abstract available


    June 2015
  50. SINGH AK, Chandra N, Bapat SA
    Evaluation of epigenetic drug targeting of heterogenous tumor cell fractions using potential biomarkers of response in ovarian cancer.
    Clin Cancer Res. 2015 Jun 30. pii: clincanres.0505.2015.
    PubMed     Text format     Abstract available


  51. KOBAYASHI Y, Kashima H, Wu RC, Jung JG, et al
    Mevalonate Pathway Antagonist Inhibits Proliferation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.
    Clin Cancer Res. 2015 Jun 24. pii: clincanres.3368.2014.
    PubMed     Text format     Abstract available


  52. GUO Y, Kenney SR Jr, Cook LS, Adams SF, et al
    A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients.
    Clin Cancer Res. 2015 Jun 12. pii: clincanres.0461.2015.
    PubMed     Text format     Abstract available


    May 2015
  53. DAMELIN M, Bankovich A, Park A, Aguilar J, et al
    Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells To Result In Sustained Tumor Regressions.
    Clin Cancer Res. 2015 May 26. pii: clincanres.0695.2015.
    PubMed     Text format     Abstract available


    January 2015
  54. REISS KA, Herman JM, Zahurak M, Brade A, et al
    A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.
    Clin Cancer Res. 2015;21:68-76.
    PubMed     Text format     Abstract available


    October 2014
  55. ZHONG Q, Peng HL, Zhao X, Zhang L, et al
    Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Clin Cancer Res. 2014 Oct 27. pii: clincanres.1816.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: